Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;52(3):445-457.
doi: 10.1016/j.ecl.2023.01.003. Epub 2023 Feb 26.

Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Shima Dowla Anwar  1 , Christy Foster  2 , Ambika Ashraf  3
Affiliations
Review

Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Shima Dowla Anwar et al. Endocrinol Metab Clin North Am. 2023 Sep.

Abstract

Dyslipidemia has been linked metabolic-associated fatty liver disease (MAFLD). Several genes and transcription factors involved in lipid metabolism can increase susceptibility to MAFLD. Multiple parallel 'hits' have been proposed for developing hepatic steatosis, NASH, and MAFLD, including insulin resistance and subsequent free fatty acid excess, de novo lipogenesis, and excessive hepatic triglyceride and cholesterol deposition in the liver. This lead to defective beta-oxidation in the mitochondria and VLDL export and increased inflammation. Given the significant cardiovascular risk, dyslipidemia associated with MAFLD should be managed by lifestyle changes and lipid-lowering agents such as statins, fenofibrate, and omega-3 fatty acids, with judicious use of insulin-sensitizing agents, and adequate control of dysglycemia.

Keywords: Dyslipidemia; Eicosapent ethyl; Fibrate; MAFLD; NAFLD; Statin.

PubMed Disclaimer